Asakayama General Hospital

The trials here

What the 2 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease2 trials
• Schizophrenia1 trial

Phase

• Phase 32 trials

Status

• Recruiting2 trials

Lead sponsor

• Karuna Therapeutics, Inc., a Bristol Myers Squibb company2 trials

Running trials

• Recruiting

  A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

  NCT06585787· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

  Contact: Kazue Kamae, Site 7509

• Recruiting

  Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

  NCT05980949· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

  Contact: Kazue Kamae, Site 7509

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease2 recruiting
• Schizophrenia1 recruiting